Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Next Previous
Trial Profile

A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia
  • Focus Adverse reactions
  • Acronyms FOURIER OLE
  • Sponsors Amgen

    • Most Recent Events

    • 06 Mar 2023 Results assessing reduction in total cardiovascular events with the Evolocumab in patients with cardiovascular disease in the combined fourier and fourier Ole studies, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.
    • 01 Mar 2023 Results published in the Amgen media release.
    • 01 Mar 2023 According to Amgen media release, new data from this study will be presented at the American College of Cardiology's 72nd annual scientific session together with World Heart Federation's World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA from 4th to 6th March 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top